The Patient-Centered Outcomes Research Institute (PCORI) has approved $83m to fund 26 patient-centered, comparative clinical effectiveness research (CER) studies on a range of conditions and patient populations.
About $29.5m will support studies on caring for people affected with hepatitis C virus (HCV). Awards totaling around $7.4m will fund research on rare conditions in response to PCORI's offer of a special pool of funding for supportingt rare disease research.
The HCV studies will include national advocacy organizations, professional associations, and stakeholder groups in their research design and implementation.
Labels: funding, hepatitis C, research